Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MapLight Therapeutics, Inc. (MPLT)
USD37.33
-0.58 (-1.53%)
US NASDAQ Healthcare Biotechnology
Address
800 Chesapeake Drive 94063
Redwood City, CA, US
Redwood City, CA, US
CEO
Christopher A. Kroeger
Website
maplightrx.com
IPO
2025-10-24
CIK 1770069 ISIN US56565P1030
Description
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD37.33
-0.58 (-1.53%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
362.3K
Beta
2.07
Float Shares
300.3K
Free Float %
38.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.91% | +5.39% | -4.39% | +66.55% | +109.86% | +63.52% | +56.65% | +56.65% | +56.65% | +56.65% | +56.65% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
37.33
Low
28.00
-25.0%
Consensus
33.80
-9.5%
Median
32.00
-14.3%
High
45.00
+20.5%
DCF (Unlevered)
0.93
-97.5%
DCF (Levered)
0.93
-97.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | +2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
45.00
+20.5%
|
| Last Quarter | 1 |
45.00
+20.5%
|
| Last Year | 5 |
33.80
-9.5%
|
| All Time | 5 |
33.80
-9.5%
|
Quality scores
Altman Z-Score
-1.44
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-95.7% Q1'26: -148.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-106.3% Q1'26: -270.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.3% Q1'26: +9.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 5 EPS Ana. |
Dec 2028 6 EPS Ana. |
Dec 2029 3 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
— – —
|
—
— – —
|
—
— – —
|
13.15M
13.15M – 13.15M
|
90.02M
90.02M – 90.02M
+584.6% YoY
|
| EBITDA |
-168.51M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-169.08M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-161.15M
est: -301.62M (+46.6%)
|
-229.67M
-236.41M – -181.25M
+23.9% YoY
|
-190.90M
-235.82M – -145.98M
+16.9% YoY
|
-204.27M
-243.01M – -165.53M
-7.0% YoY
|
-179.05M
-179.05M – -179.05M
+12.3% YoY
|
-157.97M
-157.97M – -157.97M
+11.8% YoY
|
| SGA |
30.73M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.66
est: -7.08 (+48.3%)
|
-4.82
-5.37 – -4.12
+31.9% YoY
|
-4.43
-5.36 – -3.32
+8.2% YoY
|
-4.72
-5.52 – -3.76
-6.6% YoY
|
-4.07
-4.07 – -4.07
+13.8% YoY
|
-3.59
-3.59 – -3.59
+11.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
28
Total invested
52.74M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
28
-46 vs prev Q
New positions
9
Closed positions
55
Increased
16
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NOVO HOLDINGS A/S | 3.69M +3.7M (+100.0%) | 64.76M +64.8M (+100.0%) | 8.90% +8.899 pp | 5.03% +5.029 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 2 | FCPM III SERVICES B.V. | 3.23M +3.2M (+100.0%) | 56.67M +56.7M (+100.0%) | 7.79% +7.788 pp | 7.43% +7.429 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 3 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 2.80M +2.8M (+100.0%) | 49.17M +49.2M (+100.0%) | 6.76% +6.757 pp | 0.03% +0.031 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 4 | GOLDMAN SACHS GROUP INC | 1.94M +1.9M (+100.0%) | 34.03M +34.0M (+100.0%) | 4.68% +4.676 pp | 0.00% +0.004 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 5 | BLACKROCK, INC. | 1.10M +1.1M (+100.0%) | 19.24M +19.2M (+100.0%) | 2.64% +2.644 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 6 | NAN FUNG GROUP HOLDINGS LTD | 971.3K +971.3K (+100.0%) | 17.06M +17.1M (+100.0%) | 2.34% +2.344 pp | 15.27% +15.270 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 7 | 5AM VENTURE MANAGEMENT, LLC | 950.0K +950.0K (+100.0%) | 16.69M +16.7M (+100.0%) | 2.29% +2.293 pp | 5.25% +5.246 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 8 | SANOFI | 912.0K +912.0K (+100.0%) | 16.02M +16.0M (+100.0%) | 2.20% +2.202 pp | 5.16% +5.161 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 9 | VANGUARD GROUP INC | 869.7K +869.7K (+100.0%) | 15.28M +15.3M (+100.0%) | 2.10% +2.099 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 10 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 611.4K +611.4K (+100.0%) | 10.74M +10.7M (+100.0%) | 1.48% +1.476 pp | 4.15% +4.153 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 11 | PERCEPTIVE ADVISORS LLC | 550.0K +550.0K (+100.0%) | 9.66M +9.7M (+100.0%) | 1.33% +1.328 pp | 0.17% +0.172 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 12 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 522.3K +522.3K (+100.0%) | 9.17M +9.2M (+100.0%) | 1.26% +1.261 pp | 5.32% +5.322 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 13 | SIREN, L.L.C. | 450.0K +450.0K (+100.0%) | 7.90M +7.9M (+100.0%) | 1.09% +1.086 pp | 0.24% +0.236 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 389.0K +389.0K (+100.0%) | 6.83M +6.8M (+100.0%) | 0.94% +0.939 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 15 | VESTAL POINT CAPITAL, LP | 385.0K +385.0K (+100.0%) | 6.76M +6.8M (+100.0%) | 0.93% +0.929 pp | 0.23% +0.230 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 16 | BAKER BROS. ADVISORS LP | 364.7K +364.7K (+100.0%) | 6.41M +6.4M (+100.0%) | 0.88% +0.880 pp | 0.04% +0.038 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 17 | JAIN GLOBAL LLC | 327.7K +327.7K (+100.0%) | 5.76M +5.8M (+100.0%) | 0.79% +0.791 pp | 0.03% +0.028 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 18 | BLUE OWL CAPITAL HOLDINGS LP | 327.1K +327.1K (+100.0%) | 5.74M +5.7M (+100.0%) | 0.79% +0.789 pp | 0.43% +0.430 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 19 | STATE STREET CORP | 229.5K +229.5K (+100.0%) | 4.03M +4.0M (+100.0%) | 0.55% +0.554 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 20 | LAZARD ASSET MANAGEMENT LLC | 207.5K +207.5K (+100.0%) | 3.64M +3.6M (+100.0%) | 0.50% +0.501 pp | 0.01% +0.006 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 21 | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 199.2K +199.2K (+100.0%) | 3.50M +3.5M (+100.0%) | 0.48% +0.481 pp | 0.71% +0.705 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 22 | CITADEL ADVISORS LLC | 190.1K +190.1K (+100.0%) | 3.34M +3.3M (+100.0%) | 0.46% +0.459 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 23 | FREESTONE GROVE PARTNERS LP | 183.8K +183.8K (+100.0%) | 3.23M +3.2M (+100.0%) | 0.44% +0.444 pp | 0.02% +0.023 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 24 | TFG ASSET MANAGEMENT GP LTD | 164.5K +164.5K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.40% +0.397 pp | 0.61% +0.609 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 25 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 147.9K +147.9K (+100.0%) | 2.60M +2.6M (+100.0%) | 0.36% +0.357 pp | 0.00% +0.003 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 26 | DAFNA CAPITAL MANAGEMENT LLC | 143.8K +143.8K (+100.0%) | 2.53M +2.5M (+100.0%) | 0.35% +0.347 pp | 0.59% +0.587 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 27 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 138.4K +138.4K (+100.0%) | 2.43M +2.4M (+100.0%) | 0.33% +0.334 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 28 | NORTHERN TRUST CORP | 119.6K +119.6K (+100.0%) | 2.10M +2.1M (+100.0%) | 0.29% +0.289 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 29 | SEVEN GRAND MANAGERS, LLC | 100.0K +100.0K (+100.0%) | 1.76M +1.8M (+100.0%) | 0.24% +0.241 pp | 0.13% +0.134 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 30 | STEMPOINT CAPITAL LP | 100.0K +100.0K (+100.0%) | 1.76M +1.8M (+100.0%) | 0.24% +0.241 pp | 0.30% +0.301 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 31 | BURKEHILL GLOBAL MANAGEMENT, LP | 75.0K +75.0K (+100.0%) | 1.32M +1.3M (+100.0%) | 0.18% +0.181 pp | 0.09% +0.087 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 32 | AMERIPRISE FINANCIAL INC | 66.9K +66.9K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.16% +0.161 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 33 | DIADEMA PARTNERS LP | 63.8K +63.8K (+100.0%) | 1.12M +1.1M (+100.0%) | 0.15% +0.154 pp | 0.19% +0.193 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 34 | ORBIMED ADVISORS LLC | 56.0K +56.0K (+100.0%) | 952.0K +952.0K (+100.0%) | 0.14% +0.135 pp | 0.02% +0.020 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 35 | TUDOR INVESTMENT CORP ET AL | 47.8K +47.8K (+100.0%) | 840.3K +840.3K (+100.0%) | 0.12% +0.116 pp | 0.00% +0.002 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 36 | MARSHALL WACE, LLP | 39.7K +39.7K (+100.0%) | 696.8K +696.8K (+100.0%) | 0.10% +0.096 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 37 | BANK OF AMERICA CORP /DE/ | 37.8K +37.8K (+100.0%) | 664.3K +664.3K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 38 | TD ASSET MANAGEMENT INC | 37.0K +37.0K (+100.0%) | 649.2K +649.2K (+100.0%) | 0.09% +0.089 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 39 | BANK OF NEW YORK MELLON CORP | 35.9K +35.9K (+100.0%) | 629.8K +629.8K (+100.0%) | 0.09% +0.087 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 40 | BARCLAYS PLC | 26.4K +26.4K (+100.0%) | 464.0K +464.0K (+100.0%) | 0.06% +0.064 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 41 | MORGAN STANLEY | 23.2K +23.2K (+100.0%) | 407.9K +407.9K (+100.0%) | 0.06% +0.056 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 42 | PERSISTENT ASSET PARTNERS LTD | 21.8K +21.8K (+100.0%) | 382.3K +382.3K (+100.0%) | 0.05% +0.053 pp | 0.17% +0.172 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 43 | NUVEEN, LLC | 20.2K +20.2K (+100.0%) | 354.8K +354.8K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 44 | GHISALLO CAPITAL MANAGEMENT LLC | 20.0K +20.0K (+100.0%) | 351.3K +351.3K (+100.0%) | 0.05% +0.048 pp | 0.02% +0.016 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 45 | WELLS FARGO & COMPANY/MN | 18.7K +18.7K (+100.0%) | 328.2K +328.2K (+100.0%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 46 | UBS GROUP AG | 18.3K +18.3K (+100.0%) | 321.3K +321.3K (+100.0%) | 0.04% +0.044 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 47 | OXFORD ASSET MANAGEMENT LLP | 17.8K +17.8K (+100.0%) | 312.0K +312.0K (+100.0%) | 0.04% +0.043 pp | 0.13% +0.127 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 48 | MILLENNIUM MANAGEMENT LLC | 13.9K +13.9K (+100.0%) | 244.9K +244.9K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 49 | RHUMBLINE ADVISERS | 13.6K +13.6K (+100.0%) | 239.6K +239.6K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 50 | LYNX1 CAPITAL MANAGEMENT LP | 13.5K +13.5K (+100.0%) | 236.7K +236.7K (+100.0%) | 0.03% +0.033 pp | 0.05% +0.048 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 51 | INVESCO LTD. | 13.0K +13.0K (+100.0%) | 227.8K +227.8K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 52 | DEUTSCHE BANK AG\ | 11.9K +11.9K (+100.0%) | 209.6K +209.6K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 53 | WALLEYE CAPITAL LLC | 11.7K +11.7K (+100.0%) | 205.3K +205.3K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 54 | LMR PARTNERS LLP | 10.0K +10.0K (+100.0%) | 175.7K +175.7K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 55 | METLIFE INVESTMENT MANAGEMENT, LLC | 9.8K +9.8K (+100.0%) | 172.1K +172.1K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 56 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 7.8K +7.8K (+100.0%) | 137.3K +137.3K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 57 | JPMORGAN CHASE & CO | 6.7K +6.7K (+100.0%) | 118.4K +118.4K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 58 | NEW YORK STATE COMMON RETIREMENT FUND | 5.3K +5.3K (+100.0%) | 93.1K +93.1K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 59 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 4.0K +4.0K (+100.0%) | 70.0K +70.0K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 60 | BNP PARIBAS ARBITRAGE, SNC | 3.5K +3.5K (+100.0%) | 60.7K +60.7K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 61 | STRS OHIO | 3.0K +3.0K (+100.0%) | 52.7K +52.7K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 62 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.9K +2.9K (+100.0%) | 50.4K +50.4K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 63 | LEGAL & GENERAL GROUP PLC | 1.6K +1.6K (+100.0%) | 29.0K +29.0K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 64 | AMERITAS INVESTMENT PARTNERS, INC. | 1.4K +1.4K (+100.0%) | 24.1K +24.1K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.001 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 65 | RUSSELL INVESTMENTS GROUP, LTD. | 1.3K +1.3K (+100.0%) | 23.5K +23.5K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 66 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 1.0K +1.0K (+100.0%) | 18.3K +18.3K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 67 | FMR LLC | 904.00 +904.0 (+100.0%) | 15.9K +15.9K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 68 | SBI SECURITIES CO., LTD. | 607.00 +607.0 (+100.0%) | 10.7K +10.7K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 69 | ROYAL BANK OF CANADA | 582.00 +582.0 (+100.0%) | 10.0K +10.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 70 | STERLING CAPITAL MANAGEMENT LLC | 519.00 +519.0 (+100.0%) | 9.1K +9.1K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 71 | AMALGAMATED BANK | 530.00 +530.0 (+100.0%) | 9.0K +9.0K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 72 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 500.00 +500.0 (+100.0%) | 8.8K +8.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 73 | CITIGROUP INC | 383.00 +383.0 (+100.0%) | 6.7K +6.7K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
| 74 | FARTHER FINANCE ADVISORS, LLC | 120.00 +120.0 (+100.0%) | 2.1K +2.1K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.57 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 52 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.87% | 502.0K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.18% | 65.4K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.18% | 19.65M | 0.35% |
| 4 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.09% | 2.57M | 0.55% |
| 5 | iShares Micro-Cap ETF IWC | 0.09% | 1.36M | 0.60% |
| 6 | Fidelity Disruptive Medicine ETF FMED | 0.08% | 37.7K | 0.50% |
| 7 | Pacer WealthShield ETF PWS | 0.04% | 9.1K | 0.60% |
| 8 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.02% | 154.8K | 0.96% |
| 9 | iShares Russell 2000 Growth ETF IWO | 0.02% | 3.30M | 0.24% |
| 10 | Vanguard Russell 2000 Growth ETF VTWG | 0.02% | 276.6K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
789.3K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher A. Kroeger | Founder, President, Chief Executive Officer & Director | 1M | — |
| Erin Pennock Foff | Chief Medical Officer | 745.9K | — |
| Vishwas Setia | Chief Financial Officer | 634.4K | male |
| Robert C. Malenka | Co-Founder, Member of Scientific Advisory Board & Director | 147.4K | — |
| Karoly Nikolich | Founder | — | — |
| Kristopher L. Hanson | General Counsel & Secretary | — | male |
| Karl Deisseroth | Co-Founder & Member of Scientific Advisory Board | — | — |
| James Woodruff Lillie | Chief Scientific Officer | — | — |
| Jonathan Gillis | Chief Administrative & Accounting Officer | — | male |
| Anatol Kreitzer | Chief Discovery Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MPLT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
